Should We Continue Methylphenidate Treatment Despite Orofacial or Extremity Dyskinesias?

Objective & Hypothesis:ttention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric disease affecting 5.3% of school-aged children.

📊

Key Findings & Data:Methylphenidate is the primary stimulant, which has been used widely more than 60 years to treat ADHD.

💡

Conclusion & Impact:Despite dyskinesia, one more chance may be given to methylphenidate treatment.

🔬Design:Research Article

📍Scope:Comprehensive Sample

⚙️Variables:Domain Parameters

Abstract

ttention-deficit/hyperactivity disorder (ADHD) is the most common neuropsychiatric disease affecting 5.3% of school-aged children. Methylphenidate is the primary stimulant, which has been used widely more than 60 years to treat ADHD. In this paper 3 cases with orofacial and/or limb dyskinesia after methylphenidate administration are reported. In 2 of our patients, continuation of the methylphenidate treatment did not cause recurrent dyskinesia. We thought that despite dyskinetic side effects, in cases with normal IQ level, continuation of methylphenidate treatment may be safe and do not cause any recurrent dyskinetic movements. Despite dyskinesia, one more chance may be given to methylphenidate treatment.

🔖

Cite This Article

HATİPOGLU, S., TARAKCİOGLU, M. C., KAZANCI, S. Y., SAGLAM, N. O., BULBUL, L. (2022). Should We Continue Methylphenidate Treatment Despite Orofacial or Extremity Dyskinesias?. Klinik Psikofarmakoloji Bülteni, Cilt: 25 - Sayı: 4, 399–402. https://ajindex.com/articles/573973

📄 Full Text PDF Viewer

Open in New Tab ↗

↗New Tab

📄

PDF görüntüleyici hazırlanıyor...

References (1)

Polanczyk G, Rohde LA. Epidemiology of attention-deficit/hyperactivity disorder across the lifespan. Curr Opin Psychiatry 2007;20(4):386-92. [CrossRef] 2. Findling RL. Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review. Clin Ther 2008;30(5):942-57. [CrossRef] 3. Kimko HC, Cross JT, Abernethy DR. Pharmacokinetics and clinical effectiveness of methylphenidate. Clin Pharmacokinet 1999;37(6):457-70. [CrossRef] 4. Efron D, Jarman F, Barker M. Side effects of methylphenidate and dexamphetamine in children with attention deficit hyperactivity disorder: a double-blind, crossover trial. Pediatrics 1997;100(4):662-6. [CrossRef] 5. Bruggisser M, Bodmer M, Liechti ME. Severe toxicity due to injected but not oral or nasal abuse of methylphenidate tablets. Swiss Med Wkly 2011;141:w13267. [CrossRef] 6. Gormez V, Avery B, Mann H. Switching from immediate release to sustained release methylphenidate in the treatment of children and adolescents with attention deficit/hyperactivity disorder. Eur Rev Med Pharmacol Sci 2013;17(17):2345-9. 7. Childress A, Sallee FR. The use of methylphenidate hydrochloride extended-release oral suspension for the treatment of ADHD. Expert Rev Neurother 2013;13(9):979-88. [CrossRef] 8. Rosenberg D, Holttum J, Gershon S. Textbook of pharmacotherapy for child and adolescent psychiatric disorders: Antipsychotic agents. New York: Brunner/Mazel, 1994:211-6. 9. Waugh JL. Acute dyskinetic reaction in a healthy toddler following methylphenidate ingestion. Pediatr Neurol 2013;49(1):58-60. [CrossRef] 10. Ince E, Algedik P, Demirdogen ES, Emul M, Demir T. The Relationship between acute dyskinesia with a single dose of methylphenidate and recent risperidone discontinuation in a child with attention-deficit/hyperactivity disorder. J Child Adolesc Psychopharmacol 2015;25(4):378-9. [CrossRef] 11. Karabanov AV, Illarioshkin SN. Possibilities of treatment of dystonic syndromes with akineton. Zh Nevrol Psikhiatr Im S S Korsakova 2012;112(9):41-6. 12. Yilmaz AE, Donmez A, Orun E, Tas T, Isik B, Sonmez FM. Methylphenidate-induced acute orofacial and extremity dyskinesia. J Child Neurol 2013;28(6):781-3. [CrossRef] 13. Gara L, Roberts W. Adverse response to methylphenidate in combination with valproic acid. J Child Adolesc Psychopharmacol 2000;10(1):39-43. [CrossRef] 14. Balázs J, Besnyo M, Gádoros J. Methylphenidate-induced orofacial and extremity dyskinesia. J Child Adolesc Psychopharmacol 2007;17(3):378-81. [CrossRef]